• PN: B111218

COMPONENTS

45x Ab-conjugated beads (S5P11 - human VEGF-D Ab-bead). PN: B111218A. One vial containing 100 µL of anti-human VEGF-D conjugated to AimPlex Bead S5P11.

25x Biotin-detection Ab (human VEGF-D Biotin-dAb). PN: B111218B. One vial containing 100 µL of biotinylated anti-human VEGF-D.

Lyophilized Standard Mix-Human Group 3 Panel A, 8-Plex. PN: HG30008. One vial containing lyophilized recombinant human Fractalkine, LIF, TNFβ, VEGF-D, I-TAC, MIP-1α, MIP-1β, and TIM-1.  Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human VEGF-D/FIGF.  Can be multiplexed with other analytes in Human Group 3.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 10 pg/mL

Quantitation range:

LLOQ: < 20 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 3: Negligible

Sample volume: 15 µL/test

Description:

Vascular Endothelial Growth Factor D (VEGF-D) or C-fos-induced growth factor (FIGF) is a vascular endothelial growth factor is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors. VEGF-D is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin. The structure and function of this protein is similar to those of vascular endothelial growth factor C. Diseases associated with FIGF include kidney angiomyolipoma and glioblastoma multiforme.

References:

1.      Maruyama K, Sugano S (Jan 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1-2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.

2.      Orlandini M, Marconcini L, Ferruzzi R, Oliviero S (Oct 1996). "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family". Proceedings of the National Academy of Sciences of the United States of America. 93 (21): 11675–80. doi:10.1073/pnas.93.21.11675. PMC 38117Freely accessible. PMID 8876195.

3.      Yamada Y, Nezu J, Shimane M, Hirata Y (Jun 1997). "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D". Genomics. 42 (3): 483–8. doi:10.1006/geno.1997.4774. PMID 9205122.

4.      Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (Oct 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1-2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.